Zhonghua Zhong Liu Za Zhi. 2021 Jun 23;43(6):622-628. doi: 10.3760/cma.j.cn112152-20210413-00312.
Bone-modifying agents currently include bisphosphonates and desumumab, which are the main drugs for the treatment of malignant tumor bone metastasis, hypercalcemia and osteoporosis. Due to its wide clinical application, the adverse events of this kind of drugs are gradually increasing and affecting the quality of life of patients. Therefore, it needs to arouse the attention of the majority of medical personnel. Based on the substantial evidence, the expert committee has thoroughly discussed the management of adverse reactions of bone modifying agents and put forward reasonable suggestions, to guide clinicians in the safety management of such drugs.
目前，骨改良药物包括双膦酸盐类和地舒单抗，它们是治疗恶性肿瘤骨转移、高钙血症和骨质疏松症的主要药物。由于其临床应用广泛，这类药物的不良事件逐渐增多，影响患者生活质量。因此，需要引起广大医务人员的重视。基于充分的证据，专家委员会深入讨论了骨改良药物不良反应的管理，并提出合理建议，以指导临床医生对此类药物进行安全管理。
